List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Overview
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Companies Involved in Therapeutics Development
Chronos Therapeutics Ltd
Eisai Co Ltd
Eolas Therapeutics Inc
Idorsia Pharmaceutical Ltd
Indivior Plc
Inexia Ltd
Johnson & Johnson
Merck & Co Inc
OXonium Therapeutics
Taisho Pharmaceutical Holdings Co Ltd
Yangtze River Pharmaceutical Group
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles
ACT-539313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-010018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daridorexant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EORA-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INDV-2000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-3215 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lemborexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Mollecules to Antagonize HCRTR1 for Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suvorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TS-142 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YZJ-1139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Dormant Products
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Product Development Milestones
Featured News & Press Releases
Jun 30, 2021: Eisai launches in-house developed anti-insomnia drug Dayvigo (Lemborexant) in Hong Kong
Jun 09, 2021: Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021
Jun 09, 2021: Eisai to present latest data of Lemborexant at 35th Annual Sleep Meeting
Mar 10, 2021: FDA accepts the new drug application for review of Idorsia's daridorexant for the treatment of adult patients with insomnia
Mar 03, 2021: Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia
Mar 02, 2021: New Drug Approval for in-house developed anti-insomnia drug Dayvigo (Lemborexant) in Hong Kong
Feb 04, 2021: Health Canada authorizes DAYVIGO (lemborexant)
Nov 02, 2020: Eisai to present on lemborexant at Digital CTAD 2020
Oct 28, 2020: Eisai to present on lemborexant at 13th Clinical Trials on Alzheimer's Disease (CTAD) conference
Aug 28, 2020: Eisai presents new analyses from phase 3 studies of DAYVIGO (lemborexant) CIV for the treatment of insomnia in adult patients at Virtual SLEEP 2020
Aug 28, 2020: Daridorexant Phase 3 results in insomnia presented at SLEEP 2020
Aug 25, 2020: Eisai to present latest data of lemborexant at 34th Annual Sleep Meeting (SLEEP 2020)
Aug 13, 2020: Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020
Aug 06, 2020: Idorsia Japan confirms daridorexant dose response in Japanese patients with insomnia - preparation for a local registration program advancing
Jul 22, 2020: Eisai to present latest data on Lemborexant at the Alzheimer's Association International Conference (AAIC) 2020
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Chronos Therapeutics Ltd, 2021
Pipeline by Eisai Co Ltd, 2021
Pipeline by Eolas Therapeutics Inc, 2021
Pipeline by Idorsia Pharmaceutical Ltd, 2021
Pipeline by Indivior Plc, 2021
Pipeline by Inexia Ltd, 2021
Pipeline by Johnson & Johnson, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by OXonium Therapeutics, 2021
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
Pipeline by Yangtze River Pharmaceutical Group, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

Companies Mentioned
• Chronos Therapeutics Ltd
• Eisai Co Ltd
• Eolas Therapeutics Inc
• Idorsia Pharmaceutical Ltd
• Indivior Plc
• Inexia Ltd
• Johnson & Johnson
• Merck & Co Inc
• OXonium Therapeutics
• Taisho Pharmaceutical Holdings Co Ltd
• Yangtze River Pharmaceutical Group